At the recommended Phase 3 dose of 200 mg vepdegestrant in combination with palbociclib, patients achieved a median progression-free survival of 13.9 months
Acquisition encompasses a portfolio of RLT programs across a range of solid tumor indications
Recommendation based on CAPItello-291 results which showed the Truqap combination reduced the risk of disease progression or death by 50%
Additional data in pregnant adults who are Virologically suppressed reinforce safety and tolerability profile of Biktarvy in broad range of people with HIV
Versavo is the first Dr. Reddy's biosimilar product to be approved and launched in the UK
The drug will target specific genetic mutations prevalent in certain types of cancers
The validations confirm the completion of the applications and commence the scientific review process
Highlighting fully integrated organization, robust portfolio, and strategic priorities to drive long-term sustainable growth
The initiative, “Change the Odds: Uniting to Improve Cancer Outcomes” aims to enhance awareness of and access to cancer screening, clinical trials and support
Submission to be reviewed under FDA real-time oncology review and Project Orbis
Subscribe To Our Newsletter & Stay Updated
